Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Zeno Group

    - PMLiVE

    Minds + Assembly Launches Assembled Intelligence and Adds Stratevi to Expand Market Access and HEOR Solutions

    New York, NY — 10.23.2025 — Minds + Assembly, a leading healthcare marketing firm, today announced the launch of Assembled Intelligence, an integrated communications and commercialization platform designed to unite...

    BOLDSCIENCE

    Millennial Physicians And Digital Health Services

    Can Millennial Physicians and Digital Health Services Fix the Patient-Doctor Relationship?

    Wilmington Healthcare

    - PMLiVE

    Stada opens books to let formal bidding commence

    Cinven, Advent International and Bain Capital now have opportunity to revise their bids

    - PMLiVE

    Advent tops Cinven offer for Stada as third suitor looms

    Values the OTC and generics specialist at €3.6bn, with offer open until 27 February

    - PMLiVE

    Allergan adds Zeltiq to M&A roster in $2.48n deal

    Expands aesthetic pharma business with “best-in-class” body contouring system

    - PMLiVE

    Seattle Genetics signs $2bn deal for Immunomedics’ cancer drug

    Buys rights to breast cancer drug candidate that could be be in line for FDA approval by year end

    - PMLiVE

    Stada confirms Cinven as one of two takeover bidders

    Private equity group offers €3.6bn for the generics and over-the-counter medicines manufacturer

    - PMLiVE

    Cello Health expands with Defined Health acquisition

    Builds US presence with biotech-focused strategy specialist

    Celgene building

    Celgene pays $300m upfront for immunology start-up Delinia

    Broadens its pipeline with autoimmune disease candidate due to start trials in 2018

    Actelion HQ Switzerland

    J&J agrees $30bn deal to acquire Actelion

    Swiss biotech to retain control of early-stage pipeline as J&J takes minority stake in R&D spin-out

    - PMLiVE

    Merck pays Vertex $230m upfront for cancer programmes

    Licences four DNA damage and repair programmes with first-in-class or best-in-class potential

    - PMLiVE

    Ipsen buys cancer business from stripped down Merrimack

    Deal includes pancreatic cancer therapy Onivyde which it hopes will gain first-line approval

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links